top of page


Nov 30, 2022

Press Release - PhageTech, Inc. (PhageTech), a privately held company pioneering a novel point-of-care diagnostic system, today announced the completion of enrollment in its trial of the CarePoint Electrochemical ELISA (CarePoint-ELISA) and Virus BioResistor (VBR) for bladder cancer screening. The trial was conducted at three Orange County, CA area hospitals and Vanderbilt University Medical Center in Nashville, TN, all specializing in bladder cancer treatment.

Sept 2022

PhageTech, Inc. (PhageTech), was announced as winner of the 2022 UCI Chao Family Comprehensive Cancer Center “Pitch Day Award”. The award is granted annually to support promising new companies developing novel treatment and diagnostic solutions to cancer.

Mar 19, 2021

Press Release - PhageTech Clinical Trial Start

Apr. 24, 2020

UCI Beall Applied Innovation Screens UCI Life Science Startups Focused on COVID-19 Countermeasures

Feb. 06, 2020

UC Irvine chemistry professors develop method for early cancer detection

May 29, 2017

Phagetech, LLC

Oct. 01, 2015

EvoNexus company PhageTech closes $2.4 million Series A financing for commercialization of one- minute blood and urine test.

bottom of page